{"id":"xilonix","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT03207724","NCT01965613","NCT02138422","NCT01767857"],"aliases":["MABp1, CA-18C3"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Xilonix","companyId":"janssen-research-development-llc","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Janssen Research & Development, LLC","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Xilonix","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03207724","phase":"Phase 1","title":"A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia","status":"COMPLETED","sponsor":"Andrew Hendifar, MD","isPivotal":false,"enrollment":16,"indication":"Pancreatic Cancer, Cachexia","completionDate":"2020-10-27"},{"nctId":"NCT01965613","phase":"Phase 2","title":"A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":10,"indication":"Pyoderma Gangrenosum","completionDate":"2016-12-31"},{"nctId":"NCT02138422","phase":"Phase 3","title":"A Double Blind, Placebo Controlled Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory to Standard Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":true,"enrollment":276,"indication":"Symptomatic Colorectal Cancer, Advanced Colorectal Cancer","completionDate":"2015-11-30"},{"nctId":"NCT01767857","phase":"Phase 3","title":"Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","isPivotal":true,"enrollment":643,"indication":"Metastatic Colorectal Cancer","completionDate":"2017-06-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}